FDA Approves Bevacizumab for Platinum-Sensitive Ovarian Cancer

6 dicembre 2016 – The FDA has expanded the approval for bevacizumab (Avastin) in ovarian cancer to include patients with platinum-sensitive recurrent disease as part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to Genentech, which developed the drug. The approval is based on results from 2 randomized controlled phase III studies, GOG-0213 and OCEANS. GOG-0213 demonstrated that … (leggi tutto)